Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure-Reference-Cited by-同舟云学术

Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure

Published:2000-03 Issue:3 Volume:35 Page:714-721
ISSN:0735-1097
Container-title:Journal of the American College of Cardiology
language:en
Short-container-title:Journal of the American College of Cardiology

Author:

Tsutamoto Takayoshi,Wada Atsuyuki,Maeda Keiko,Mabuchi Naoko,Hayashi Masaru,Tsutsui Takashi,Ohnishi Masato,Sawaki Masahide,Fujii Masanori,Matsumoto Takehiro,Kinoshita Masahiko

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference41 articles.

1. Hemodynamic and neurohumoral effects of the angiotensin II antagonist losartan in patients with congestive heart failure;Gottlieb;Circulation,1993

2. Losartan in heart failure. Hemodynamic effects and tolerability;Crozier;Circulation,1995

3. Comparison of the effects of losartan and enalapril on clinical status exercise performance in patients with moderate or severe chronic heart failure;Dickstein;J Am Coll Cardiol,1995

4. Randomized trial of losartan versus captopril in patients over 65 with heart failure;Pitt;Lancet,1997

5. Angiotensin II-forming pathways in normal and failing human hearts;Urata;Circ Res,1990

Cited by 165 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulation and immunopharmacology in heart failure;Nature Reviews Cardiology;2023-09-14

2. Pre and postnatal exposure to 900 MHz electromagnetic fields induce inflammation and oxidative stress, and alter renin-angiotensin system components differently in male and female offsprings;Life Sciences;2023-05

3. Cardiovascular benefits of air purifier in patients with stable coronary artery disease: A randomized single-blind crossover study;Frontiers in Public Health;2023-01-09

4. Pharmacogenomic study of heart failure and candesartan response from the CHARM programme;ESC Heart Failure;2022-06-23

5. Pathophysiology of Circulating Biomarkers and Relationship With Vascular Aging: A Review of the Literature From VascAgeNet Group on Circulating Biomarkers, European Cooperation in Science and Technology Action 18216;Frontiers in Physiology;2021-12-14